Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An inherited or acquired condition characterized by abnormally increased levels of methemoglobin in the blood.
Biomarker and diagnostic research for methemoglobinemia has been reported in the published literature.
No approved treatments are currently available for methemoglobinemia. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for methemoglobinemia, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for methemoglobinemia. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
No clinical trials have been registered for methemoglobinemia.
240 publications have been identified in PubMed for methemoglobinemia. Research spans Case Report / Case Series (67%), Review / Meta-Analysis (10%), and Epidemiology / Natural History (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 161 | 67% |
Data assembled from 3 of 12 sources · Last updated Oct 3, 2026, 5:08 PM UTC
Designated
Exclusivity End |
|---|
Designation Status |
|---|
methylene blue | methylene blue | Fera Pharmaceuticals, LLC | 2012 | — | Designated |
Gene therapy approaches for methemoglobinemia have been reported in the published literature.
View trials for methemoglobinemia
25 |
10% |
Disease patterns and progression | 21 | 9% |
Laboratory research | 17 | 7% |
Clinical study results | 8 | 3% |
Other research | 5 | 2% |
Testing and diagnosis research | 2 | 1% |
New treatment approaches | 1 | 0% |
Barlow K (2026). [PMID: 41853735](https://pubmed.ncbi.nlm.nih.gov/41853735/). *AJP Rep*. [Case Report / Case Series]
Meignien M (2026). [PMID: 40968002](https://pubmed.ncbi.nlm.nih.gov/40968002/). *La Revue de medecine interne*. [Case Report / Case Series]
Miruzzi L (2026). [PMID: 41571394](https://pubmed.ncbi.nlm.nih.gov/41571394/). *BMJ Case Rep*. [Case Report / Case Series]
Sakach JC (2026). [PMID: 41694054](https://pubmed.ncbi.nlm.nih.gov/41694054/). *Gynecol Oncol Rep*. [Case Report / Case Series]
Neven J (2026). [PMID: 41639689](https://pubmed.ncbi.nlm.nih.gov/41639689/). *Orphanet journal of rare diseases*. [Clinical Trial Publication]
Smith BA (2026). [PMID: 40492955](https://pubmed.ncbi.nlm.nih.gov/40492955/). *Journal of pharmacy practice*. [Review / Meta-Analysis]
Abdallah A (2026). [PMID: 42137699](https://pubmed.ncbi.nlm.nih.gov/42137699/). *Cureus*. [Case Report / Case Series]
Al-Hajjaj R (2026). [PMID: 41574980](https://pubmed.ncbi.nlm.nih.gov/41574980/). *Annals of African medicine*. [Review / Meta-Analysis]
Chandran T (2026). [PMID: 42158211](https://pubmed.ncbi.nlm.nih.gov/42158211/). *Int J Endocrinol Metab*. [Epidemiology / Natural History]
Santiago B (2026). [PMID: 41988351](https://pubmed.ncbi.nlm.nih.gov/41988351/). *Cureus*. [Case Report / Case Series]